左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果分析

发布时间：2019-07-05 09:54

【摘要】：目的:评估左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果,为我省急性心力衰竭患者治疗方案的合理选用提供参考。方法:根据全球SURVIVE临床试验数据,结合目前我省医疗及消费水平,采用成本-效果分析法分别对左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果及结果敏感度进行分析。结果:对于急性心力衰竭患者,短期(5 d)给予左西孟旦治疗的人均总成本为10 490.00元,多巴酚丁胺为6 637.18元。成本-效果分析及敏感度试验结果均表明,我省人均国内生产总值(GDP)左西孟旦相较于多巴酚丁胺的增量成本-效果比我省3倍GDP。结论:在我省目前的经济水平下,对于急性心力衰竭患者,采用左西孟旦的治疗方案较传统药物具有成本-效果优势。
[Abstract]:Objective: to evaluate the cost-effectiveness of levosimendan and dobutamine in the treatment of acute heart failure, and to provide reference for the rational selection of treatment schemes for patients with acute heart failure in our province. Methods: according to the global SURVIVE clinical trial data and the current medical and consumption levels in our province, the cost-effectiveness and outcome sensitivity of levosimendan and dobutamine in the treatment of acute heart failure were analyzed by cost-effectiveness analysis. Results: for patients with acute heart failure, the total cost per capita was 10 490.00 yuan and dobutamine 6 637.18 yuan in a short term (5 days). The results of cost-effectiveness analysis and sensitivity test show that the incremental cost-effectiveness of (GDP) per capita in our province is three times higher than that of dobutamine compared with dobutamine. The results of cost-effectiveness analysis and sensitivity test show that the incremental cost-effectiveness of Zoximendan is three times higher than that of dobutamine. Conclusion: at the current economic level in our province, the treatment of acute heart failure with Zuoximendan has the advantage of cost-effectiveness compared with the traditional drug.
【作者单位】：武汉大学人民医院药学部;
【分类号】：R541.6

【相似文献】